{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:51:04Z","timestamp":1794246664884,"version":"4.9.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ30992 to R.R.Z"],"award-info":[{"award-number":["2022JJ30992 to R.R.Z"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tumor Treating Fields (TTFields) is a physical therapy that uses moderate frequency (100\u2013300\u2009kHz) and low-intensity (1\u20133\u2009V\/cm) alternating electric fields to inhibit tumors. Currently, the Food and Drug Administration approves TTFields for treating recurrent or newly diagnosed glioblastoma (GBM) and malignant pleural mesothelioma (MPM). The classical mechanism of TTFields is mitotic inhibition by hindering the formation of tubulin and spindle. In addition, TTFields inhibits cell proliferation, invasion, migration and induces cell death, such as apoptosis, autophagy, pyroptosis, and cell cycle arrest. Meanwhile, it regulates immune function and changes the permeability of the nuclear membrane, cell membrane, and blood-brain barrier. Based on the current researches on TTFields in various tumors, this review comprehensively summarizes the in-vitro effects, changes in pathways and molecules corresponding to relevant parameters of TTFields (frequency, intensity, and duration). In addition, radiotherapy and chemotherapy are common tumor treatments. Thus, we also pay attention to the sequence and dose when TTFields combined with radiotherapy or chemotherapy. TTFields has inhibitory effects in a variety of tumors. The study of TTFields mechanism is conducive to subsequent research. How to combine common tumor therapy such as radiotherapy and chemotherapy to obtain the maximum benefit is also a problem that\u2019s worthy of our attention.<\/jats:p>","DOI":"10.1038\/s41420-022-01206-y","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T07:03:14Z","timestamp":1665471794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy"],"prefix":"10.1038","volume":"8","author":[{"given":"Guilong","family":"Tanzhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dikang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-0615","authenticated-orcid":false,"given":"Rongrong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"1206_CR1","doi-asserted-by":"publisher","first-page":"10152","DOI":"10.1073\/pnas.0702916104","volume":"104","author":"ED Kirson","year":"2007","unstructured":"Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA. 2007;104:10152\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1206_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11060-020-03466-z","volume":"147","author":"A Song","year":"2020","unstructured":"Song A, Bar-Ad V, Martinez N, Glass J, Andrews DW, Judy K, et al. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. J Neurooncol. 2020;147:653\u201361.","journal-title":"J Neurooncol"},{"key":"1206_CR3","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48:2192\u2013202.","journal-title":"Eur J Cancer"},{"key":"1206_CR4","doi-asserted-by":"publisher","first-page":"ii60","DOI":"10.1093\/neuonc\/noaa215.243","volume":"22","author":"J-J Zhu","year":"2020","unstructured":"Zhu J-J, O\u2019Donnell RT, Goldlust S, Ram Z. CTNI-77. EF-19, a post-approval registry study of Tumor Treating Fields (TTfields) in recurrent glioblastoma (rGBM). Neuro Oncol. 2020;22:ii60\u2013ii.","journal-title":"Neuro Oncol"},{"key":"1206_CR5","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1053\/j.seminoncol.2014.09.008","volume":"41","author":"AA Kanner","year":"2014","unstructured":"Kanner AA, Wong ET, Villano JL, Ram Z, Investigators EF. Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A system versus best physician\u2019s choice chemotherapy. Semin Oncol 2014;41:S25\u201334.","journal-title":"Semin Oncol"},{"key":"1206_CR6","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017;318:2306\u201316.","journal-title":"JAMA"},{"key":"1206_CR7","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.ijrobp.2019.04.008","volume":"104","author":"MT Ballo","year":"2019","unstructured":"Ballo MT, Urman N, Lavy-Shahaf G, Grewal J, Bomzon Z, Toms S. Correlation of tumor treating fields dosimetry to survival outcomes in newly diagnosed glioblastoma: a large-scale numerical simulation-based analysis of data from the phase 3 EF-14 randomized trial. Int J Radiat Oncol Biol Phys. 2019;104:1106\u201313.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1206_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","volume":"4","author":"MJB Taphoorn","year":"2018","unstructured":"Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4:495\u2013504.","journal-title":"JAMA Oncol"},{"key":"1206_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.lungcan.2013.06.025","volume":"81","author":"M Pless","year":"2013","unstructured":"Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A phase I\/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer. 2013;81:445\u201350.","journal-title":"Lung Cancer"},{"key":"1206_CR10","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","volume":"20","author":"GL Ceresoli","year":"2019","unstructured":"Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019;20:1702\u20139.","journal-title":"Lancet Oncol"},{"key":"1206_CR11","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:1405\u201314.","journal-title":"Lancet"},{"key":"1206_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","volume":"7","author":"GV Scagliotti","year":"2019","unstructured":"Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019;7:569\u201380.","journal-title":"Lancet Respir Med"},{"key":"1206_CR13","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","volume":"35","author":"F Grosso","year":"2017","unstructured":"Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, et al. Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-meso trial. J Clin Oncol. 2017;35:3591\u2013600.","journal-title":"J Clin Oncol"},{"key":"1206_CR14","doi-asserted-by":"crossref","unstructured":"Gkika E, Grosu AL, Macarulla Mercade T, Cubillo Gracian A, Brunner TB, Schultheiss M, et al. Tumor treating fields concomitant with sorafenib in advanced hepatocellular cancer: Results of the HEPANOVA Phase II Study. Cancers. 2022;14:1568.","DOI":"10.3390\/cancers14061568"},{"key":"1206_CR15","doi-asserted-by":"publisher","first-page":"CT186","DOI":"10.1158\/1538-7445.AM2020-CT186","volume":"80","author":"E Gkika","year":"2020","unstructured":"Gkika E, Brunner T, Thimme R, Grosu A-L. Abstract CT186: HEPANOVA: interim safety analysis from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC). Cancer Res 2020;80:CT186\u2013CT.","journal-title":"Cancer Res"},{"key":"1206_CR16","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1200\/JCO.2017.35.15_suppl.5580","volume":"35","author":"I Vergote","year":"2017","unstructured":"Vergote I, Moos RV, Manso L, Sessa C. INNOVATE: a phase II study of TTFields (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian cancer\u2014Updated safety and efficacy results. J Clin Oncol. 2017;35:5580.","journal-title":"J Clin Oncol"},{"key":"1206_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ygyno.2018.07.018","volume":"150","author":"I Vergote","year":"2018","unstructured":"Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study. Gynecol Oncol. 2018;150:471\u20137.","journal-title":"Gynecol Oncol"},{"key":"1206_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/jco.2016.34.4_suppl.269","volume":"34","author":"F Rivera","year":"2016","unstructured":"Rivera F, Gallego J, Guillen C, Benavides M, Lopez-Martin JA, Betticher DC, et al. PANOVA: a pilot study of TTFields concomitant with gemcitabine for front-line therapy in patients with advanced pancreatic adenocarcinoma. J Clin Oncol. 2016;34:269.","journal-title":"J Clin Oncol"},{"key":"1206_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pan.2018.10.004","volume":"19","author":"F Rivera","year":"2019","unstructured":"Rivera F, Benavides M, Gallego J, Guillen-Ponce C, Lopez-Martin J, Kung M. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study. Pancreatology 2019;19:64\u201372.","journal-title":"Pancreatology"},{"key":"1206_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.171","volume":"8","author":"M Silginer","year":"2017","unstructured":"Silginer M, Weller M, Stupp R, Roth P. Biological activity of tumor-treating fields in preclinical glioma models. Cell Death Dis. 2017;8:e2753.","journal-title":"Cell Death Dis"},{"key":"1206_CR21","first-page":"4582","volume":"11","author":"WS Lee","year":"2021","unstructured":"Lee WS, Seo SJ, Chung HK, Park JW, Kim JK, Kim EH. Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy. Am J Cancer Res. 2021;11:4582\u201394.","journal-title":"Am J Cancer Res"},{"key":"1206_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2019.10.003","volume":"217","author":"NK Karanam","year":"2020","unstructured":"Karanam NK, Ding L, Aroumougame A, Story MD. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy. Transl Res. 2020;217:33\u201346.","journal-title":"Transl Res"},{"key":"1206_CR23","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1080\/09553002.2020.1838658","volume":"96","author":"Y Jo","year":"2020","unstructured":"Jo Y, Oh G, Gi Y, Sung H, Joo EB, Lee S, et al. Tumor treating fields (TTF) treatment enhances radiation-induced apoptosis in pancreatic cancer cells. Int J Radiat Biol. 2020;96:1528\u201333.","journal-title":"Int J Radiat Biol"},{"key":"1206_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-017-0941-6","volume":"12","author":"M Giladi","year":"2017","unstructured":"Giladi M, Munster M, Schneiderman RS, Voloshin T, Porat Y, Blat R, et al. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiat Oncol. 2017;12:206.","journal-title":"Radiat Oncol"},{"key":"1206_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.136","volume":"8","author":"NK Karanam","year":"2017","unstructured":"Karanam NK, Srinivasan K, Ding L, Sishc B, Saha D, Story MD. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines. Cell Death Dis. 2017;8:e2711.","journal-title":"Cell Death Dis"},{"key":"1206_CR26","doi-asserted-by":"crossref","unstructured":"Jo Y, Kim EH, Sai S, Kim JS, Cho JM, Kim H, et al. Functional biological activity of sorafenib as a tumor-treating field sensitizer for glioblastoma therapy. Int J Mol Sci. 2018;19:3684.","DOI":"10.3390\/ijms19113684"},{"key":"1206_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-229","volume":"10","author":"RS Schneiderman","year":"2010","unstructured":"Schneiderman RS, Shmueli E, Kirson ED, Palti Y. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. BMC Cancer. 2010;10:229.","journal-title":"BMC Cancer"},{"key":"1206_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lungcan.2021.08.011","volume":"160","author":"H Mumblat","year":"2021","unstructured":"Mumblat H, Martinez-Conde A, Braten O, Munster M, Dor-On E, Schneiderman RS, et al. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models. Lung Cancer. 2021;160:99\u2013110.","journal-title":"Lung Cancer"},{"key":"1206_CR29","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/carcin\/bgz150","volume":"41","author":"L Li","year":"2020","unstructured":"Li L, Hu C, Lu C, Zhang K, Han R, Lin C, et al. Applied electric fields suppress osimertinib-induced cytotoxicity via inhibiting FOXO3a nuclear translocation through AKT activation. Carcinogenesis 2020;41:600\u201310.","journal-title":"Carcinogenesis"},{"key":"1206_CR30","doi-asserted-by":"crossref","unstructured":"Lee YJ, Cho JM, Sai S, Oh JY, Park JA, Oh SJ, et al. 5-fluorouracil as a tumor-treating field-sensitizer in colon cancer therapy. Cancers. 2019;11:1999.","DOI":"10.3390\/cancers11121999"},{"key":"1206_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6649-9-1","volume":"9","author":"ED Kirson","year":"2009","unstructured":"Kirson ED, Schneiderman RS, Dbaly V, Tovarys F, Vymazal J, Itzhaki A, et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009;9:1.","journal-title":"BMC Med Phys"},{"key":"1206_CR32","first-page":"3475","volume":"10","author":"JY Kim","year":"2020","unstructured":"Kim JY, Jo Y, Oh HK, Kim EH. Sorafenib increases tumor treating fields-induced cell death in glioblastoma by inhibiting STAT3. Am J Cancer Res. 2020;10:3475\u201386.","journal-title":"Am J Cancer Res"},{"key":"1206_CR33","first-page":"3935","volume":"11","author":"JS Kim","year":"2021","unstructured":"Kim JS, Cho JM, Kim H, Jeong YK, Kim JK, Kim EH. Tumor treating fields can effectively overcome trastuzumab resistant breast cancer multiplication. Am J Cancer Res. 2021;11:3935\u201345.","journal-title":"Am J Cancer Res"},{"key":"1206_CR34","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.seminoncol.2014.09.006","volume":"41","author":"M Giladi","year":"2014","unstructured":"Giladi M, Weinberg U, Schneiderman RS, Porat Y, Munster M, Voloshin T, et al. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Semin Oncol 2014;41:S35\u201341.","journal-title":"Semin Oncol"},{"key":"1206_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pan.2013.11.009","volume":"14","author":"M Giladi","year":"2014","unstructured":"Giladi M, Schneiderman RS, Porat Y, Munster M, Itzhaki A, Mordechovich D, et al. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology 2014;14:54\u201363.","journal-title":"Pancreatology"},{"key":"1206_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11060-017-2534-5","volume":"134","author":"E Chang","year":"2017","unstructured":"Chang E, Pohling C, Beygui N, Patel CB, Rosenberg J, Ha DH, et al. Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields. J Neurooncol. 2017;134:259\u201368.","journal-title":"J Neurooncol"},{"key":"1206_CR37","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1002\/ijc.30406","volume":"139","author":"T Voloshin","year":"2016","unstructured":"Voloshin T, Munster M, Blatt R, Shteingauz A, Roberts PC, Schmelz EM, et al. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int J Cancer. 2016;139:2850\u20138.","journal-title":"Int J Cancer"},{"key":"1206_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s10544-018-0339-8","volume":"20","author":"KF Lei","year":"2018","unstructured":"Lei KF, Hsieh SC, Goh A, Kuo RL, Tsang NM. Proliferation arrest, selectivity, and chemosensitivity enhancement of cancer cells treated by a low-intensity alternating electric field. Biomed Microdevices. 2018;20:90.","journal-title":"Biomed Microdevices"},{"key":"1206_CR39","doi-asserted-by":"publisher","first-page":"LBA2007","DOI":"10.1200\/jco.2010.28.18_suppl.lba2007","volume":"28","author":"R Stupp","year":"2010","unstructured":"Stupp R, Kanner A, Engelhard H, Heidecke V, Taillibert S, Lieberman FS, et al. A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma. J Clin Oncol. 2010;28:LBA2007\u2013LBA.","journal-title":"J Clin Oncol"},{"key":"1206_CR40","doi-asserted-by":"publisher","first-page":"v46","DOI":"10.1093\/neuonc\/nov208.06","volume":"17","author":"H Brozova","year":"2015","unstructured":"Brozova H, Lucas A, Salmaggi A, Vymazal J. BMET-06COMET: a phase II randomized study of TTFields versus supportive care in non-small cell lung cancer patients with 1-5 brain metastases-initial safety results. Neuro Oncol. 2015;17:v46\u2013v.","journal-title":"Neuro Oncol"},{"key":"1206_CR41","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/cns.13750","volume":"27","author":"H Wu","year":"2021","unstructured":"Wu H, Yang L, Liu H, Zhou D, Chen D, Zheng X, et al. Exploring the efficacy of tumor electric field therapy against glioblastoma: an in vivo and in vitro study. CNS Neurosci Ther. 2021;27:1587\u2013604.","journal-title":"CNS Neurosci Ther"},{"key":"1206_CR42","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/cns.13441","volume":"26","author":"H Wu","year":"2020","unstructured":"Wu H, Wang C, Liu J, Zhou D, Chen D, Liu Z, et al. Evaluation of a tumor electric field treatment system in a rat model of glioma. CNS Neurosci Ther. 2020;26:1168\u201377.","journal-title":"CNS Neurosci Ther"},{"key":"1206_CR43","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","volume":"64","author":"ED Kirson","year":"2004","unstructured":"Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64:3288\u201395.","journal-title":"Cancer Res"},{"key":"1206_CR44","doi-asserted-by":"publisher","first-page":"715031","DOI":"10.3389\/fonc.2021.715031","volume":"11","author":"B Linder","year":"2021","unstructured":"Linder B, Schiesl A, Voss M, Rodel F, Hehlgans S, Gullulu O, et al. Dexamethasone treatment limits efficacy of radiation, but does not interfere with glioma cell death induced by tumor treating fields. Front Oncol. 2021;11:715031.","journal-title":"Front Oncol"},{"key":"1206_CR45","doi-asserted-by":"crossref","unstructured":"Branter J, Estevez-Cebrero M, Diksin M, Griffin M, Castellanos-Uribe M, May S, et al. Genome-wide expression and anti-proliferative effects of electric field therapy on pediatric and adult brain tumors. Int J Mol Sci. 2022;23:1982.","DOI":"10.3390\/ijms23041982"},{"key":"1206_CR46","doi-asserted-by":"crossref","unstructured":"Porat Y, Giladi M, Schneiderman RS, Blat R, Shteingauz A, Zeevi E, et al. Determining the optimal inhibitory frequency for cancerous cells using Tumor Treating Fields (TTFields). J Vis Exp. 2017:55820.","DOI":"10.3791\/55820"},{"key":"1206_CR47","doi-asserted-by":"publisher","first-page":"65125","DOI":"10.18632\/oncotarget.11372","volume":"7","author":"EH Kim","year":"2016","unstructured":"Kim EH, Song HS, Yoo SH, Yoon M. Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis. Oncotarget 2016;7:65125\u201336.","journal-title":"Oncotarget"},{"key":"1206_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/srep18046","volume":"5","author":"M Giladi","year":"2015","unstructured":"Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5:18046.","journal-title":"Sci Rep"},{"key":"1206_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41420-018-0079-9","volume":"4","author":"AF Kessler","year":"2018","unstructured":"Kessler AF, Frombling GE, Gross F, Hahn M, Dzokou W, Ernestus RI, et al. Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition. Cell Death Discov. 2018;4:12.","journal-title":"Cell Death Discov"},{"key":"1206_CR50","doi-asserted-by":"publisher","first-page":"107881","DOI":"10.1016\/j.bioelechem.2021.107881","volume":"141","author":"T Pfeifer","year":"2021","unstructured":"Pfeifer T, Bai L, Gladkich J, Gross W, Liu L, Herr I, et al. Therapy of pancreatic cancer with alternating electric fields: limitations of the method. Bioelectrochemistry 2021;141:107881.","journal-title":"Bioelectrochemistry"},{"key":"1206_CR51","doi-asserted-by":"crossref","unstructured":"Voloshin T, Schneiderman RS, Volodin A, Shamir RR, Kaynan N, Zeevi E, et al. Tumor Treating Fields (TTFields) hinder cancer cell motility through regulation of microtubule and acting dynamics. Cancers. 2020;12:3016.","DOI":"10.3390\/cancers12103016"},{"key":"1206_CR52","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00262-020-02534-7","volume":"69","author":"T Voloshin","year":"2020","unstructured":"Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman RS, et al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother. 2020;69:1191\u2013204.","journal-title":"Cancer Immunol Immunother"},{"key":"1206_CR53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/147323001204000109","volume":"40","author":"H Chen","year":"2012","unstructured":"Chen H, Liu R, Liu J, Tang J. Growth inhibition of malignant melanoma by intermediate frequency alternating electric fields, and the underlying mechanisms. J Int Med Res. 2012;40:85\u201394.","journal-title":"J Int Med Res"},{"key":"1206_CR54","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jocn.2016.10.042","volume":"36","author":"PA Clark","year":"2017","unstructured":"Clark PA, Gaal JT, Strebe JK, Pasch CA, Deming DA, Kuo JS, et al. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. J Clin Neurosci. 2017;36:120\u20134.","journal-title":"J Clin Neurosci"},{"key":"1206_CR55","doi-asserted-by":"publisher","first-page":"6630","DOI":"10.1038\/s41388-019-0882-7","volume":"38","author":"EH Kim","year":"2019","unstructured":"Kim EH, Jo Y, Sai S, Park MJ, Kim JY, Kim JS, et al. Tumor-treating fields induce autophagy by blocking the Akt2\/miR29b axis in glioblastoma cells. Oncogene 2019;38:6630\u201346.","journal-title":"Oncogene"},{"key":"1206_CR56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1063\/1.4902112","volume":"105","author":"H Jeong","year":"2014","unstructured":"Jeong H, Sung J, Oh SI, Jeong S, Koh EK, Hong S, et al. Inhibition of brain tumor cell proliferation by alternating electric fields. Appl Phys Lett. 2014;105:5.","journal-title":"Appl Phys Lett"},{"key":"1206_CR57","doi-asserted-by":"publisher","first-page":"153303381984500","DOI":"10.1177\/1533033819845008","volume":"18","author":"Y Jo","year":"2019","unstructured":"Jo Y, Sung J, Jeong H, Hong S, Jeong YK, Kim EH, et al. Effectiveness of a fractionated therapy scheme in tumor treating fields therapy. Technol Cancer Res Treat. 2019;18:1533033819845008.","journal-title":"Technol Cancer Res Treat"},{"key":"1206_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1085-9","volume":"9","author":"A Shteingauz","year":"2018","unstructured":"Shteingauz A, Porat Y, Voloshin T, Schneiderman RS, Munster M, Zeevi E, et al. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). Cell Death Dis. 2018;9:1074.","journal-title":"Cell Death Dis"},{"key":"1206_CR59","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646\u201374.","journal-title":"Cell"},{"key":"1206_CR60","doi-asserted-by":"publisher","first-page":"738801","DOI":"10.3389\/fonc.2021.738801","volume":"11","author":"L Bai","year":"2021","unstructured":"Bai L, Pfeifer T, Gross W, De La Torre C, Zhao S, Liu L, et al. Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer. Front Oncol. 2021;11:738801.","journal-title":"Front Oncol"},{"key":"1206_CR61","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41420-018-0106-x","volume":"4","author":"Y Jo","year":"2018","unstructured":"Jo Y, Hwang SG, Jin YB, Sung J, Jeong YK, Baek JH, et al. Selective toxicity of tumor treating fields to melanoma: an in vitro and in vivo study. Cell Death Discov. 2018;4:46.","journal-title":"Cell Death Discov"},{"key":"1206_CR62","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s13258-021-01105-z","volume":"43","author":"H Jeong","year":"2021","unstructured":"Jeong H, Jo Y, Yoon M, Hong S. Thymidine decreases the DNA damage and apoptosis caused by tumor-treating fields in cancer cell lines. Genes Genomics. 2021;43:995\u20131001.","journal-title":"Genes Genomics"},{"key":"1206_CR63","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41420-018-0130-x","volume":"4","author":"E Chang","year":"2018","unstructured":"Chang E, Patel CB, Pohling C, Young C, Song J, Flores TA, et al. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discov. 2018;4:113.","journal-title":"Cell Death Discov"},{"key":"1206_CR64","first-page":"1423","volume":"12","author":"Y Jo","year":"2022","unstructured":"Jo Y, Han YI, Lee E, Seo J, Oh G, Sung H, et al. The combination of tumor treating fields and hyperthermia has synergistic therapeutic effects in glioblastoma cells by downregulating STAT3. Am J Cancer Res. 2022;12:1423\u201332.","journal-title":"Am J Cancer Res"},{"key":"1206_CR65","doi-asserted-by":"crossref","unstructured":"Neuhaus E, Zirjacks L, Ganser K, Klumpp L, Schuler U, Zips D, et al. Alternating Electric Fields (TTFields) activate Cav1.2 channels in human glioblastoma cells. Cancers. 2019;11:110.","DOI":"10.3390\/cancers11010110"},{"key":"1206_CR66","doi-asserted-by":"publisher","first-page":"e0125269","DOI":"10.1371\/journal.pone.0125269","volume":"10","author":"N Gera","year":"2015","unstructured":"Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS ONE. 2015;10:e0125269.","journal-title":"PLoS ONE"},{"key":"1206_CR67","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4161\/auto.22558","volume":"9","author":"S Stingele","year":"2013","unstructured":"Stingele S, Stoehr G, Storchova Z. Activation of autophagy in cells with abnormal karyotype. Autophagy 2013;9:246\u20138.","journal-title":"Autophagy"},{"key":"1206_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68473-6","volume":"10","author":"YJ Lee","year":"2020","unstructured":"Lee YJ, Seo HW, Baek JH, Lim SH, Hwang SG, Kim EH. Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment. Sci Rep. 2020;10:12272.","journal-title":"Sci Rep"},{"key":"1206_CR69","doi-asserted-by":"crossref","unstructured":"Chen D, Le SB, Hutchinson TE, Calinescu AA, Sebastian M, Jin D, et al. Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma. J Clin Invest. 2022;132:e149258.","DOI":"10.1172\/JCI149258"},{"key":"1206_CR70","doi-asserted-by":"crossref","unstructured":"Lee J, Grabowski MM, Lathia JD. Tumor Treating Fields: killing two birds with one stone. J Clin Invest. 2022;132:e159073.","DOI":"10.1172\/JCI159073"},{"key":"1206_CR71","doi-asserted-by":"publisher","first-page":"vi180","DOI":"10.1093\/neuonc\/noab196.713","volume":"23","author":"T Voloshin","year":"2021","unstructured":"Voloshin T, Koltun B, Koren L, Porat Y, Volodin A, Kaynan N, et al. EXTH-74. increasing cancer cell membrane permeability through application of Tumor Treating Fields (TTfields). Neuro-Oncol. 2021;23:vi180\u2013vi.","journal-title":"Neuro-Oncol"},{"key":"1206_CR72","doi-asserted-by":"publisher","first-page":"100536","DOI":"10.1016\/j.bas.2021.100536","volume":"1","author":"E Salvador","year":"2021","unstructured":"Salvador E, Kessler AF, Giniunaite A, Burek M, Brami CT, Voloshin T, et al. Application of Tumor Treating Fields (TTFields) to open the blood brain barrier (BBB) as future CNS drug delivery strategy. Brain Spine 2021;1:100536.","journal-title":"Brain Spine"},{"key":"1206_CR73","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/jcmm.12088","volume":"17","author":"ML Pall","year":"2013","unstructured":"Pall ML. Electromagnetic fields act via activation of voltage-gated calcium channels to produce beneficial or adverse effects. J Cell Mol Med. 2013;17:958\u201365.","journal-title":"J Cell Mol Med"},{"key":"1206_CR74","doi-asserted-by":"crossref","unstructured":"Aguilar AA, Ho MC, Chang E, Carlson KW, Natarajan A, Marciano T, et al. Permeabilizing cell membranes with electric fields. Cancers. 2021;13:2283.","DOI":"10.3390\/cancers13092283"},{"key":"1206_CR75","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.1158\/1538-7445.AM2020-6251","volume":"80","author":"E Salvador","year":"2020","unstructured":"Salvador E, Kessler AF, H\u00f6rmann J, Burek M, Brami CT, Sela TV, et al. Abstract 6251: Blood brain barrier opening by TTFields: a future CNS drug delivery strategy. Cancer Res 2020;80:6251.","journal-title":"Cancer Res"},{"key":"1206_CR76","doi-asserted-by":"crossref","unstructured":"Brami CT, Salvador E, Kessler AF, Burek M, Voloshin T, Giladi M, et al. Transient opening of the blood brain barrier by Tumor Treating Fields (TTFields). In: Proceedings of the American Association for Cancer Research Annual Meeting 2021. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 279.","DOI":"10.1158\/1538-7445.AM2021-279"},{"key":"1206_CR77","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1200\/JCO.2020.38.15_suppl.2551","volume":"38","author":"E Salvador","year":"2020","unstructured":"Salvador E, Kessler A, Hoermann J, Domroese D, Schaeffer C, Burek M, et al. Tumor treating fields effects on the blood-brain barrier in vitro and in vivo. J Clin Oncol. 2020;38:2551.","journal-title":"J Clin Oncol"},{"key":"1206_CR78","doi-asserted-by":"publisher","first-page":"vi82","DOI":"10.1093\/neuonc\/noz175.336","volume":"21","author":"E Schulz","year":"2019","unstructured":"Schulz E, Kessler AF, Salvador E, Domr\u00f6se D, Burek M, Tempel Brami C, et al. EXTH-02. The blood brain barrier (BBB) permeability is altered by Tumor Treating Fields (TTFields) in vivo. Neuro-Oncol. 2019;21:vi82\u2013vi.","journal-title":"Neuro-Oncol"},{"key":"1206_CR79","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/1538-7445.AM2019-252","volume":"79","author":"AF Kessler","year":"2019","unstructured":"Kessler AF, Schaeffer CM, Burek M, Ruschig U, Tempel-Brami C, Voloshin T, et al. Abstract 252: Tumor treating fields (TTFields) affect blood brain barrier (BBB) integrity in vitro and in vivo. Cancer Res 2019;79:252.","journal-title":"Cancer Res"},{"key":"1206_CR80","doi-asserted-by":"publisher","first-page":"iii286","DOI":"10.1093\/neuonc\/noy139.267","volume":"20","author":"AF Kessler","year":"2018","unstructured":"Kessler AF, Schaeffer C, Burek M, Ruschig U, Ernestus R, L\u00f6hr M, et al. P04.33 Effects of Tumor Treating Fields (TTFields) on blood brain barrier (BBB) permeability. Neuro Oncol. 2018;20:iii286\u2013iii.","journal-title":"Neuro Oncol"},{"key":"1206_CR81","doi-asserted-by":"publisher","first-page":"153303382094748","DOI":"10.1177\/1533033820947481","volume":"19","author":"JY Oh","year":"2020","unstructured":"Oh JY, Lee YJ, Kim EH. Tumor-treating fields inhibit the metastatic potential of osteosarcoma cells. Technol Cancer Res Treat. 2020;19:1533033820947481.","journal-title":"Technol Cancer Res Treat"},{"key":"1206_CR82","first-page":"503","volume":"21","author":"H Simchony","year":"2019","unstructured":"Simchony H, Diamant D, Ram Z, Volovitz I. Evaluation of the compatibility of electric tumor treating fields with key anti-tumoral T-cell functions. Isr Med Assoc J. 2019;21:503.","journal-title":"Isr Med Assoc J"},{"key":"1206_CR83","doi-asserted-by":"publisher","first-page":"153303381986822","DOI":"10.1177\/1533033819868225","volume":"18","author":"JI Park","year":"2019","unstructured":"Park JI, Song KH, Jung SY, Ahn J, Hwang SG, Kim J, et al. Tumor-Treating Fields induce RAW264.7 macrophage activation via NK-kappaB\/MAPK signaling pathways. Technol Cancer Res Treat. 2019;18:1533033819868225.","journal-title":"Technol Cancer Res Treat"},{"key":"1206_CR84","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10585-009-9262-y","volume":"26","author":"ED Kirson","year":"2009","unstructured":"Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, et al. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26:633\u201340.","journal-title":"Clin Exp Metastasis"},{"key":"1206_CR85","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.semradonc.2010.06.003","volume":"20","author":"J Thoms","year":"2010","unstructured":"Thoms J, Bristow RG. DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol. 2010;20:217\u201322.","journal-title":"Semin Radiat Oncol"},{"key":"1206_CR86","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.trsl.2012.01.022","volume":"160","author":"SR Stecklein","year":"2012","unstructured":"Stecklein SR, Jensen RA. Identifying and exploiting defects in the Fanconi anemia\/BRCA pathway in oncology. Transl Res. 2012;160:178\u201397.","journal-title":"Transl Res"},{"key":"1206_CR87","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1101\/gad.195248.112","volume":"26","author":"H Kim","year":"2012","unstructured":"Kim H, D\u2019Andrea AD. Regulation of DNA cross-link repair by the Fanconi anemia\/BRCA pathway. Genes Dev. 2012;26:1393\u2013408.","journal-title":"Genes Dev"},{"key":"1206_CR88","doi-asserted-by":"publisher","first-page":"R651","DOI":"10.1016\/j.cub.2021.03.064","volume":"31","author":"ET Spiliotis","year":"2021","unstructured":"Spiliotis ET, Nakos K. Cellular functions of actin- and microtubule-associated septins. Curr Biol. 2021;31:R651\u2013R66.","journal-title":"Curr Biol"},{"key":"1206_CR89","doi-asserted-by":"publisher","first-page":"R570","DOI":"10.1016\/j.cub.2018.03.045","volume":"28","author":"A Basant","year":"2018","unstructured":"Basant A, Glotzer M. Spatiotemporal regulation of RhoA during cytokinesis. Curr Biol. 2018;28:R570\u2013R80.","journal-title":"Curr Biol"},{"key":"1206_CR90","doi-asserted-by":"publisher","first-page":"e0168641","DOI":"10.1371\/journal.pone.0168641","volume":"11","author":"MP Girouard","year":"2016","unstructured":"Girouard MP, Pool M, Alchini R, Rambaldi I, Fournier AE. RhoA proteolysis regulates the actin cytoskeleton in response to oxidative stress. PLoS ONE. 2016;11:e0168641.","journal-title":"PLoS ONE"},{"key":"1206_CR91","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.tcb.2008.02.006","volume":"18","author":"J Birkenfeld","year":"2008","unstructured":"Birkenfeld J, Nalbant P, Yoon SH, Bokoch GM. Cellular functions of GEF-H1, a microtubule-regulated Rho-GEF: is altered GEF-H1 activity a crucial determinant of disease pathogenesis? Trends Cell Biol. 2008;18:210\u20139.","journal-title":"Trends Cell Biol"},{"key":"1206_CR92","doi-asserted-by":"publisher","first-page":"618157","DOI":"10.3389\/fcell.2020.618157","volume":"8","author":"C Rinaldi","year":"2020","unstructured":"Rinaldi C, Pizzul P, Longhese MP, Bonetti D. Sensing R-loop-associated DNA damage to safeguard genome stability. Front Cell Dev Biol. 2020;8:618157.","journal-title":"Front Cell Dev Biol"},{"key":"1206_CR93","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00253-019-10257-8","volume":"104","author":"Z Xu","year":"2020","unstructured":"Xu Z, Han X, Ou D, Liu T, Li Z, Jiang G, et al. Targeting PI3K\/AKT\/mTOR-mediated autophagy for tumor therapy. Appl Microbiol Biotechnol. 2020;104:575\u201387.","journal-title":"Appl Microbiol Biotechnol"},{"key":"1206_CR94","first-page":"136","volume":"1845","author":"KS Siveen","year":"2014","unstructured":"Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta. 2014;1845:136\u201354.","journal-title":"Biochim Biophys Acta"},{"key":"1206_CR95","doi-asserted-by":"publisher","first-page":"421821","DOI":"10.1155\/2013\/421821","volume":"2013","author":"MZ Kamran","year":"2013","unstructured":"Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int. 2013;2013:421821.","journal-title":"Biomed Res Int"},{"key":"1206_CR96","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3389\/fimmu.2020.00615","volume":"11","author":"D Wan","year":"2020","unstructured":"Wan D, Jiang W, Hao J. Research advances in how the cGAS-STING pathway controls the cellular inflammatory response. Front Immunol. 2020;11:615.","journal-title":"Front Immunol"},{"key":"1206_CR97","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","volume":"13","author":"M Jiang","year":"2020","unstructured":"Jiang M, Chen P, Wang L, Li W, Chen B, Liu Y, et al. cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol. 2020;13:81.","journal-title":"J Hematol Oncol"},{"key":"1206_CR98","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. 2021;21:548\u201369.","journal-title":"Nat Rev Immunol"},{"key":"1206_CR99","doi-asserted-by":"publisher","first-page":"837589","DOI":"10.3389\/fonc.2022.837589","volume":"12","author":"P Shi","year":"2022","unstructured":"Shi P, Tian J, Ulm BS, Mallinger JC, Khoshbouei H, Deleyrolle LP, et al. Tumor treating fields suppression of ciliogenesis enhances temozolomide toxicity. Front Oncol. 2022;12:837589.","journal-title":"Front Oncol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01206-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01206-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01206-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T19:03:23Z","timestamp":1665515003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01206-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1206"],"URL":"https:\/\/doi.org\/10.1038\/s41420-022-01206-y","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"10 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"416"}}